What have we learnt from targeted anti-TNF therapy?. (7th December 2009)

• Record Type: Journal Article
• Authors: Feldmann, M; Williams, R O; Paleolog, E
• Is Part Of: Annals of the rheumatic diseases. Volume 69(2010)Supplement 1
• Page Start: i97
• Page End: i99
• Publication Date: 2009-12-07
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/ard.2009.117143
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Anti-tumour necrosis factor (anti-TNF) therapy of patients with rheumatoid arthritis dates back to 1992, when the first proof-of-principle trials were performed in London by Maini and Feldmann. Considerable studies of the mechanism of action were performed, and insights into the way in which anti-TNF therapy delivers its benefit were obtained. In this brief review, certain aspects of knowledge acquired and the many gaps will be reviewed. Focus will be on the TNF-dependent cytokine cascade and what it means, and potential new approaches to treatment. Finally, an entertaining challenge: might many or even all unmet clinical needs be dealt with through cytokine analysis?